Innate Tumor-targeted Nanozyme Overcoming Tumor Hypoxia for Cancer Theranostic Use

Overview

Journal J Adv Res

Specialties General Medicine
Science

Date 2021 Oct 4

PMID 34603790

Citations 4

Authors

Hanitrarimalala Veroniaina

Zhenghong Wu

Xiaole Qi

Affiliations

Soon will be listed here.

Abstract

Introduction: Hypoxic tumor microenvironment (TME) is the major contributor to cancer metastasis, resistance to chemotherapy, and recurrence of tumors. So far, no approved treatment has been available to overcome tumor hypoxia.

Objectives: The present study aimed to relieve tumor hypoxia via a nanozyme theranostic nanomaterial as well as providing magnetic resonance imaging (MRI)-guided therapy.

Methods: Manganese dioxide (MnO) was used for its intrinsic enzymatic activity co-loaded with the anti-cancer drug Doxorubicin (Dox) within the recombinant heavy-chain apoferritin cavity to form MnO-Dox@HFn. Following the synthesis of the nanomaterial, different characterizations were performed as well as its nanozyme-like ability. This nanoplatform recognizes tumor cells through the transferrin receptors 1 (TfR1) which are highly expressed on the surface of most cancer cells. The cellular uptake was confirmed by flow cytometry and fluorescence spectroscopy. and studies have been investigated to evaluate the hypoxia regulation, MRI ability and anti-tumor activity of MnO-Dox@HFn.

Results: Being a TME-responsive nanomaterial, MnO-Dox@HFn exerted both peroxidase and catalase activity that mainly produce massive oxygen and Mn ions. Respectively, these products relieve the unfavorable tumor hypoxia and also exhibit T1-weighted MRI with a high longitudinal relaxivity of 33.40 mM. s. The utility of MnO-Dox@HFn was broadened with their efficient anti-cancer activity proved both and .

Conclusions: MnO-Dox@HFn successfully overcome tumor hypoxia with double potentials enzymatic ability and diagnostic capacity. This investigation could ignite the future application for cancer theranostic nanozyme therapy.

Citing Articles

Hypoxia-ameliorated photothermal manganese dioxide nanoplatform for reversing doxorubicin resistance.

Chen Z, Liu Z, Zhang Q, Huang S, Zhang Z, Feng X Front Pharmacol. 2023; 14:1133011.

PMID: 36909187 PMC: 9998484. DOI: 10.3389/fphar.2023.1133011.

Application Perspectives of Nanomedicine in Cancer Treatment.

Hou S, Hasnat M, Chen Z, Liu Y, Ashraf Baig M, Liu F Front Pharmacol. 2022; 13:909526.

PMID: 35860027 PMC: 9291274. DOI: 10.3389/fphar.2022.909526.

BHLHE41 Overexpression Alleviates the Malignant Behavior of Colon Cancer Cells Induced by Hypoxia via Modulating HIF-1/EMT Pathway.

Chen S, Dong Q, Wan Z, Gao S, Tu S, Chai R Gastroenterol Res Pract. 2022; 2022:6972331.

PMID: 35615737 PMC: 9126723. DOI: 10.1155/2022/6972331.

Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis.

Zhou Q, Lu Y, Zhou J, Yang X, Wang X, Yu J J Nanobiotechnology. 2021; 19(1):361.

PMID: 34749740 PMC: 8576982. DOI: 10.1186/s12951-021-01102-0.

References

Liang R, Wei M, Evans D, Duan X . Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics. Chem Commun (Camb). 2014; 50(91):14071-81. DOI: 10.1039/c4cc03118k. View

Corbet C, Feron O . Tumour acidosis: from the passenger to the driver's seat. Nat Rev Cancer. 2017; 17(10):577-593. DOI: 10.1038/nrc.2017.77. View

Allinen M, Beroukhim R, Cai L, Brennan C, Lahti-Domenici J, Huang H . Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004; 6(1):17-32. DOI: 10.1016/j.ccr.2004.06.010. View

Jiang W, Li Q, Xiao L, Dou J, Liu Y, Yu W . Hierarchical Multiplexing Nanodroplets for Imaging-Guided Cancer Radiotherapy via DNA Damage Enhancement and Concomitant DNA Repair Prevention. ACS Nano. 2018; 12(6):5684-5698. DOI: 10.1021/acsnano.8b01508. View

Fan W, Bu W, Shen B, He Q, Cui Z, Liu Y . Intelligent MnO2 Nanosheets Anchored with Upconversion Nanoprobes for Concurrent pH-/H2O2-Responsive UCL Imaging and Oxygen-Elevated Synergetic Therapy. Adv Mater. 2015; 27(28):4155-61. DOI: 10.1002/adma.201405141. View

Liu Y, Zhen W, Jin L, Zhang S, Sun G, Zhang T . All-in-One Theranostic Nanoagent with Enhanced Reactive Oxygen Species Generation and Modulating Tumor Microenvironment Ability for Effective Tumor Eradication. ACS Nano. 2018; 12(5):4886-4893. DOI: 10.1021/acsnano.8b01893. View

Zhang Y, Qiu W, Zhang M, Zhang L, Zhang X . MnO Motor: A Prospective Cancer-Starving Therapy Promoter. ACS Appl Mater Interfaces. 2018; 10(17):15030-15039. DOI: 10.1021/acsami.8b01818. View

Huang Y, Ren J, Qu X . Nanozymes: Classification, Catalytic Mechanisms, Activity Regulation, and Applications. Chem Rev. 2019; 119(6):4357-4412. DOI: 10.1021/acs.chemrev.8b00672. View

Chen H, Tian J, He W, Guo Z . H2O2-activatable and O2-evolving nanoparticles for highly efficient and selective photodynamic therapy against hypoxic tumor cells. J Am Chem Soc. 2015; 137(4):1539-47. DOI: 10.1021/ja511420n. View

10.

Zhu P, Chen Y, Shi J . Nanoenzyme-Augmented Cancer Sonodynamic Therapy by Catalytic Tumor Oxygenation. ACS Nano. 2018; 12(4):3780-3795. DOI: 10.1021/acsnano.8b00999. View

11.

Zhao Z, Fan H, Zhou G, Bai H, Liang H, Wang R . Activatable fluorescence/MRI bimodal platform for tumor cell imaging via MnO2 nanosheet-aptamer nanoprobe. J Am Chem Soc. 2014; 136(32):11220-3. DOI: 10.1021/ja5029364. View

12.

Yang G, Xu L, Chao Y, Xu J, Sun X, Wu Y . Hollow MnO as a tumor-microenvironment-responsive biodegradable nano-platform for combination therapy favoring antitumor immune responses. Nat Commun. 2017; 8(1):902. PMC: 5638920. DOI: 10.1038/s41467-017-01050-0. View

13.

Ghaffari S, Sarrafzadeh M, Fakhroueian Z, Khorramizadeh M . Flower-like curcumin-loaded folic acid-conjugated ZnO-MPA- βcyclodextrin nanostructures enhanced anticancer activity and cellular uptake of curcumin in breast cancer cells. Mater Sci Eng C Mater Biol Appl. 2019; 103:109827. DOI: 10.1016/j.msec.2019.109827. View

14.

Song M, Liu T, Shi C, Zhang X, Chen X . Bioconjugated Manganese Dioxide Nanoparticles Enhance Chemotherapy Response by Priming Tumor-Associated Macrophages toward M1-like Phenotype and Attenuating Tumor Hypoxia. ACS Nano. 2015; 10(1):633-647. PMC: 5242343. DOI: 10.1021/acsnano.5b06779. View

15.

Bertout J, Patel S, Simon M . The impact of O2 availability on human cancer. Nat Rev Cancer. 2008; 8(12):967-75. PMC: 3140692. DOI: 10.1038/nrc2540. View

16.

Dai M, Cui P, Yu M, Han J, Li H, Xiu R . Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. J Pineal Res. 2008; 44(2):121-6. DOI: 10.1111/j.1600-079X.2007.00498.x. View

17.

Cheng X, Fan K, Wang L, Ying X, Sanders A, Guo T . TfR1 binding with H-ferritin nanocarrier achieves prognostic diagnosis and enhances the therapeutic efficacy in clinical gastric cancer. Cell Death Dis. 2020; 11(2):92. PMC: 7002446. DOI: 10.1038/s41419-020-2272-z. View

18.

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

19.

Sanna K, Rofstad E . Hypoxia-induced resistance to doxorubicin and methotrexate in human melanoma cell lines in vitro. Int J Cancer. 1994; 58(2):258-62. DOI: 10.1002/ijc.2910580219. View

20.

Li L, Munoz-Culla M, Carmona U, Lopez M, Yang F, Trigueros C . Ferritin-mediated siRNA delivery and gene silencing in human tumor and primary cells. Biomaterials. 2016; 98:143-51. DOI: 10.1016/j.biomaterials.2016.05.006. View